Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the high incidence of central nervous system (CNS) involvement in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), commenting on the importance of giving intrathecal chemotherapy prophylaxis to patients regardless of the type of induction therapy. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.